Characteristics of IDH-mutant gliomas with non-canonical IDH mutation
- PMID: 33205355
- DOI: 10.1007/s11060-020-03662-x
Characteristics of IDH-mutant gliomas with non-canonical IDH mutation
Abstract
Background: Approximately 10% of IDH-mutant gliomas harbour non-canonical IDH mutations (non-p.R132H IDH1 and IDH2 mutations).
Objective: The aim of this study was to analyse the characteristics of non-canonical IDH-mutant gliomas.
Materials and methods: We retrospectively analysed the characteristics of 166 patients with non-canonical IDH mutant gliomas and compared them to those of 155 consecutive patients with IDH1 p.R132H mutant gliomas.
Results: The median age at diagnosis was 38 years in patients with non-canonical IDH mutant gliomas and 43 years in glioma patients with IDH1 p.R132H-mutant tumours. Family history of cancer was more frequent among glioma patients harbouring non-canonical IDH mutations than in patients with IDH1 p.R132H mutations (22.2% vs 5.1%; P < 0.05). Tumours were predominantly localised in the frontal lobe regardless of the type of IDH mutation. Compared to IDH1 p.R132H-mutant gliomas, tumours with non-canonical IDH mutations were more frequently found in the infratentorial region (5.5% vs 0%; P < 0.05) and were often multicentric (4.8% vs 0.9%; P < 0.05). Compared to IDH1 P.R132H-mutant gliomas, tumours with non-canonical IDH1 mutations were more frequently astrocytomas (65.6% vs 43%, P < 0.05), while those with IDH2 mutations were more frequently oligodendrogliomas (85% vs 48.3%; P < 0.05). The median overall survival was similar in patients with IDH1 p.R132H-mutant gliomas and patients with non-canonical IDH-mutant gliomas.
Conclusion: Gliomas with non-canonical IDH mutations have distinct radiological and histological characteristics. The presence of such tumours seems to be associated with genetic predisposition to cancer development.
Keywords: Infra-tentorial gliomas; Inherited predisposition to cancer; Multicentric gliomas; Non-canonical IDH mutant gliomas.
References
-
- Yan H, McLendon R, Kos I, Riggins GJ, Reardon D, Velculescu VE et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773 - DOI
-
- Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131(6):803–820 - DOI
-
- Watanabe T, Vital A, Nobusawa S, Kleihues P, Ohgaki H (2009) Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol 117(6):653–656 - DOI
-
- Bonnet C, Thomas L, Psimaras D, Bielle F, Vauléon E, Loiseau H, Ducray F (2016) Characteristics of gliomas in patients with somatic IDH mosaicism. Acta Neuropathol Commun 4(1):1–8 - DOI
-
- Picca A, Berzero G, Bielle F, Touat M, Savatovsky J, Polivka M et al (2018) FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas. Neurology 90(23):e2086–e2094 - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
